Predictive Technology Group, Inc. (PRED) Research

Predictive Technology Group, Inc. (PRED), along with its affiliated companies, specializes in the creation and market introduction of cutting-edge molecular diagnostic and therapeutic solutions, as well as human cellular and tissue-based products (HCT/Ps). The company's operations are divided into two primary segments: Human Cellular and Tissue Products (HCT/Ps), and Diagnostics and Therapeutics. PRED offers genetic testing services like FertilityDX, which assists couples experiencing infertility, and ARTguide, a genetic test for women struggling with infertility often linked to endometriosis and other genetic conditions. In the realm of regenerative medicine, its product offerings include AmnioCyte, AmnioCyte Plus, PolyCyte, and CoreCyte. Furthermore, Predictive Technology Group has a cooperative arrangement with Atrin Pharmaceuticals LLC to advance molecular diagnostic tools, which are intended to refine the selection of patients for cancer treatments. Founded in 2005, the company initially operated under the name Global Enterprises Group, Inc., before rebranding to Predictive Technology Group, Inc. in July 2015. Its corporate headquarters are situated in Salt Lake City, Utah.

Open Predictive Technology Group, Inc. (PRED) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.